

June 2009

### **Zilico at Healthcare Innovation EXPO 2009**

Zilico participated in the first ever Healthcare Innovation EXPO showcasing the latest innovations and new ideas in healthcare from the UK and around the world which was held on 18th-19th June in London. Over the two days more than 5000 NHS front-line staff, clinicians, managers and others from patient and voluntary organisations, academics and companies, attended the event.

Medipex, a Zilico shareholder, is one of the nine regional innovation hubs of the NHS, which were exhibiting their leading companies and projects on the 'NHS Innovations' stand. Amongst the many visitors to the stand were Lord Darzi and David Nicholson. The photograph below shows Richard Clark, Medipex's CEO & NED of Zilico, presenting Zilico's portable cervical cancer diagnostic device to them as a leading example of innovation. This innovation and its early development were carried out at the Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield.



**For more information please contact:** Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; email: [sameer.kothari@zilico.co.uk](mailto:sameer.kothari@zilico.co.uk)

#### **Notes for editors:**

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two product applications are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures.

Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico (previously known as Aperio Diagnostic Ltd) has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico product applications consist of a handheld device and a base unit together with a single-use disposable sleeve for each test.